Showing 4141-4150 of 5646 results for "".
- Outlook Therapeutics Resubmits Biologics License Application to FDA for Wet AMD Drug Candidate ONS-5010https://modernod.com/news/outlook-therapeutics-re-submits-biologics-license-application-for-ons-5010-as-a-treatment-for-wet-amd-to-the-fda/2481052/Outlook Therapeutics announced it has resubmitted its biologics license application (BLA) to the FDA for ONS-5010, an investigational ophthalmic therapy which, if approved, will be branded as Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD
- iTrack Canaloplasty to be Featured at the 2022 ESCRS Annual Meetinghttps://modernod.com/news/itrack-canaloplasty-to-be-featured-at-the-2022-escrs-annual-meeting/2481051/Nova Eye Medical announced that the company’s proprietary canaloplasty technology platform (iTrack™ and iTrack™ Advance) will be featured during the official scientific program of the European Society of Cataract and Refractive Surgeons (ESCRS) 40th Congress on Septemb
- Haag-Streit Opens New Surgical Microscope Production Site in Aesch, Switzerlandhttps://modernod.com/news/haag-streit-opens-new-surgical-microscope-production-site-in-aesch-switzerland/2481047/Haag-Streit announced the opening of a new state-of-the-art microscope production site in Aesch, Switzerland. In September 2021, Haag-Streit decided to reposition and focus solely on ophthalmology and the production and future development of the
- Apellis Announces 24-Month Results in Phase 3 Studies Examining Pegcetacoplan in Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-24-month-results-showing-increased-effects-over-time-with-pegcetacoplan-in-phase-3-derby-and-oaks-studies-in-geographic-atrophy-ga/2481045/Apellis Pharmaceuticals announced topline data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Glaukos Licenses Iveena’s Investigational Keratoconus Therapyhttps://modernod.com/news/glaukos-licenses-iveenas-investigational-keratoconus-therapy/2481044/Glaukos has acquired an exclusive global license to develop and commercialize iVeena Delivery Systems' investigational pharmacologic treatment for keratoconus, IVMED-80. As part of the agreement, Glaukos paid $10 million upfront and will assume all costs associated with development
- Oculis Announces Publication of Phase 2 Data Showing Eye Drop Drug Candidate Relieves Persistent Ocular Discomfort in Severe Dry Eye Diseasehttps://modernod.com/news/oculis-announces-publication-of-phase-2-data-showing-topical-eye-drop-drug-candidate-ocs-02-relieves-persistent-ocular-discomfort-in-severe-dry-eye-disease/2481042/Oculis announced that the results of the double blinded, multicenter and placebo controlled phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on global ocular discomfort in patients with severe dry eye disease (DED) has been published by the journal C
- Study: Bioengineered Cornea Can Restore Sight to the Blind and Visually Impairedhttps://modernod.com/news/study-bioengineered-cornea-can-restore-sight-to-the-blind-and-visually-impaired/2481039/Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant, according to Link&oum
- Show Organizers Announce Reimagined Floor Plan for Vision Expo East 2023https://modernod.com/news/show-organizers-announce-reimagined-floor-plan-for-vision-expo-east-2023/2481037/The Vision Council and RX, co-organizers of Vision Expo, shared plans for a reimagined show floor layout that will debut at Vision Expo East 2023, taking place March 16–19 at the Javits Center in New York City. The new layout will feature all of Vision Expo’s Show Fl
- Visibly Becomes First FDA-Cleared Online Vision Test in the United Stateshttps://modernod.com/news/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states/2481033/Visibly, the developer of an at-home digital vision testing platform, announced that it has received 510(k) clearance from the FDA for its Visibly Digital Acuity Product (VDAP). Visibly said it is the first FDA-cleared online visual acuity test on the US market. View Eyew
- Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the-omni-surgical-system-in-patients-with-open-angle-glaucoma/2481030/Sight Sciences announced 36-month post-surgery follow-up results of the Omni Surgical System. The data demonstrate that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis, according